Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.

Matthew S Davids Gottfried von Keudell Craig A Portell Jonathon B Cohen David C Fisher Francine Foss Andrew W Roberts John F Seymour Rod A Humerickhouse Constantine S Tam

J Clin Oncol

Matthew S. Davids, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Gottfried von Keudell, Yale School of Medicine, New Haven, CT; Craig A. Portell, University of Virginia Health System, Charlottesville, VA; Jonathon B. Cohen, Winship Cancer Institute of Emory University, Atlanta, GA; David C. Fisher, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Francine Foss, Yale School of Medicine, New Haven, CT; Andrew W. Roberts, Royal Melbourne Hospital and University of Melbourne, Melbourne, Victoria, Australia; John F. Seymour, Royal Melbourne Hospital, Peter MacCallum Cancer Centre, and University of Melbourne, Melbourne, Victoria, Australia; Rod A. Humerickhouse, AbbVie, Chicago, IL; and Constantine S. Tam, Royal Melbourne Hospital, Peter MacCallum Cancer Centre, St Vincent's Hospital, and University of Melbourne, Melbourne, Victoria, Australia.

Published: October 2018

Download full-text PDF	Source
http://dx.doi.org/10.1200/JCO.18.00359	DOI Listing

Publication Analysis

Top Keywords

revised dose

dose ramp-up

ramp-up mitigate

mitigate risk

risk tumor

tumor lysis

lysis syndrome

syndrome initiating

initiating venetoclax

venetoclax patients

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!